Synta Pharmaceuticals Corp.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 2000-01-01

Employees: 51

Market Cap: -

Website: http://www.syntapharma.com

Clinical Trials

A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors

Phase 1

Suspended

Conditions: Metastatic Solid Tumors

Interventions: Drug: Elesclomol Sodium

First Posted Date: 2009-01-22

Last Posted Date: 2009-03-09

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 30

Registration Number: NCT00827203

Locations: 🇺🇸
Mayo Clinic, Rochester, Maryland, United States
🇺🇸
University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development, San Antonio, Texas, United States
🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Elesclomol Sodium
Drug: Docetaxel

First Posted Date: 2008-12-15

Last Posted Date: 2014-02-03

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 34

Registration Number: NCT00808418

Locations: 🇺🇸
Mayo Clinic, Rochester, Maryland, United States
🇺🇸
Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, California, United States
🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States

and more 2 locations

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: STA-9090

First Posted Date: 2008-06-02

Last Posted Date: 2014-09-18

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 53

Registration Number: NCT00687934

Locations: 🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸
US Oncology Dayton Oncology and Hematology, P.A, Kettering, Ohio, United States

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Phase 1

Conditions: Solid Tumors

Interventions: Drug: STA 9090 (ganetespib)

First Posted Date: 2008-06-02

Last Posted Date: 2014-09-18

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 45

Registration Number: NCT00688116

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center (BIDMC) - Cancer Center, Boston, Massachusetts, United States

and more 2 locations

A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes

Phase 2

Completed

Conditions: Active, Moderate to Severe Rheumatoid Arthritis

Interventions: Drug: STA 5326 mesylate
Drug: Placebo

First Posted Date: 2008-03-25

Last Posted Date: 2014-02-04

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 35

Registration Number: NCT00642629

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Netherlands

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Phase 3

Terminated

Conditions: Melanoma

Interventions: Drug: Elesclomol (STA-4783)
Drug: Paclitaxel

First Posted Date: 2007-08-30

Last Posted Date: 2014-03-04

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 630

Registration Number: NCT00522834

Locations: 🇺🇸
The Ohio State University., Columbus, Ohio, United States
🇺🇸
Cancer Pavilion, Pittsburgh, Pennsylvania, United States
🇺🇸
University of California San Diego Moores UCSD Cancer Center, La Jolla, California, United States

and more 96 locations

A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced or Metastatic Solid Tumors

First Posted Date: 2006-01-13

Last Posted Date: 2014-02-03

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 30

Registration Number: NCT00276913

Locations: 🇺🇸
Steven Limentani, MD, Charlotte, North Carolina, United States

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

First Posted Date: 2005-10-07

Last Posted Date: 2008-12-04

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 12

Registration Number: NCT00234741

Locations: 🇺🇸
Nih/Niaid, Bethesda, Maryland, United States

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

First Posted Date: 2005-08-30

Last Posted Date: 2008-12-04

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 282

Registration Number: NCT00138840

Locations: 🇺🇸
Maryland Digestive Disease Research, Laurel, Maryland, United States
🇺🇸
Capital Gastroenterology Consultants, P.A., Silver Spring, Maryland, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 32 locations

A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas

Phase 2

Completed

Conditions: Soft Tissue Sarcoma

First Posted Date: 2004-07-23

Last Posted Date: 2006-06-20

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 80

Registration Number: NCT00087997

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Palm Beach Cancer Institute, West Palm Beach, Florida, United States
🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

and more 23 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy